Loading
A phase 2 trial of Entrectinib in colorectal cancer and melanoma, run by Hoffmann-La Roche, active and no longer recruiting.
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is a phase 2 interventional study registered as NCT02568267 by Hoffmann-La Roche, with 534 participants enrolled, started 2015-11-19 and due to reach its primary completion in 2027-06-30. Interventions recorded: Entrectinib. Conditions listed: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms. No results are recorded here; the registry entry is the source.
Shares A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements, NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer.
Shares Entrectinib, ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements, PROFILE 1001 ROS1 expansion cohort, NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer.
Shares Entrectinib, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.